Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

-- Approximately 80% of 180 patients with recurrent glioblastoma (rGBM) in the Phase III clinical trial are expected to be randomized and enrolled by the end of December 2022 -- Phase III clinical trial evalua...

Full "IntellAsia: Resources" article